- (4) I. G. Farbenind, A.-G., French Patent 820,696 (1937); Chem. Abstr., 32, 3422 (1938).
- (5) T. Koenig and M. Deinzer, J. Amer. Chem. Soc., 90, 7014 (1968).
- (6) R. Lennaers and F. Eloy, Helv. Chim. Acta, 46, 1067 (1963).
- (7) G. Goldberg, Ber., 22, 2976 (1889).
- (8) G. Müller, ibid., 18, 2486 (1885).
- (9) V. L. Narayanan and J. Bernstein, J. Heterocycl. Chem., 3, 214 (1966).

Thiolesters of Orotic Acid[†]

Dale R. Sargent and Charles G. Skinner*

Department of Chemistry, North Texas State University, Denton, Texas 76203. Received May 25, 1972

The chemical reactivity associated with thiolesters¹ has been utilized to produce noncompetitive metabolic inhibitors.²⁻⁴ Since orotic acid is an essential intermediate in the biogenesis of pyrimidines, a series of potential metabolite analogs was prepared for biological study containing thiolester moieties. These compounds were synthesized by a direct condensation between orotoyl chloride⁵ and the appropriate thiol. The poor solubility of these derivatives precluded testing them effectively in liquid cultures, and they were accordingly examined for toxicity to microbial growth using a disk assay technique.⁶

Experimental Section

All of the thiols were purchased from commercial sources. Orotoyl chloride was prepared by a previously reported procedure⁵ and was used immediately for the condensation reaction.

All melting points were determined in open glass capillaries using a Thomas-Hoover Uni-Melt apparatus and are uncor. Microanalyses were carried out by Mrs. Delaney Blocker of the Analytical Laboratories of North Texas State University using an F & M Model 185 GPC carbon-nitrogen-hydrogen analyzer.

S-(Substituted)thiolesters of Orotic Acid (Table I). All of these deriv were prepd in a comparable fashion. A sample of 0.01 mole of

Table I. S-(Substituted)thiolesters of Orotic Acid^a



R	Mp,°C	Reaction temp, °C	Recrystn solvent	Empirical formula ^b
n-Pr	208-209	Reflux	H ₂ O	C ₈ H ₁₀ N ₂ O ₃ S
n-Bu	187-188	Reflux	AcOH-H ₂ O	C ₀ H ₁ ,N ₂ O ₃ S
n-Hept	150-151	Reflux	AcOH	$C_{12}H_{18}N_2O_3S$
n-Dec	148-149	125-150	AcOH	C15H24N2O3S
n-Tetradec	131-132	125-150	AcOH	$C_{10}H_{32}N_{2}O_{3}S$
Cyclohex	248-249	Reflux	AcOH	$C_{11}H_{14}N_{2}O_{3}S$
Benzyl	228-230	125-150	AcOH	$C_{12}H_{10}N_2O_3S$

^{*a*}Replicate syntheses gave varying yields of analytically pure products ranging between 10 and 30%. ^{*b*}All compds were analyzed for C, H, N and were within $\pm 0.3\%$ of the theoretical value.

freshly prepd orotoyl chloride was placed in a reaction flask and treated with 5-10 ml (excess) of the appropriate thiol. The react mixt was magnetically stirred and heated at the indicated temp for about 1 hr and then allowed to come to room temp with continued stirring for an additional 5 hr. The resulting ppt was taken up in warm AcOH, treated with Darco G-60, and filtered through a Celite pad. Upon cooling to room temp, a small amount of orotic acid pptd which was removed. The resulting clear filtrate was treated with H₂O

[†]This work was supported in part by a grant from the Robert A. Welch Foundation (B-342) and the North Texas State University Faculty Research Fund. to ppt the thiolesters which were recrystd and dried *in vacuo* overnight at $50-60^\circ$ prior to elemental analysis.

Biological Assays. Of the eight microorganisms studied, the *n*-propyl, *n*-butyl, and benzyl thiolesters were inhibitory to growth of Lactobacillus plantarum and Pediococcus cerevisiae at about 60 μ g/disk but were ineffective toward growth of Escherichia coli, L. bulgaricus, Leuconostoc dextranicum, Streptococcus faecalis, L. casei, and Strep. lactis at 100 μ g/disk. The other thiolesters herein reported were nontoxic at 100 μ g/disk to growth of these bacteria.

References


- (1) A. W. Baker and G. H. Harris, J. Amer. Chem. Soc., 82, 1923 (1960).
- (2) J. M. Ravel, T. J. McCord, C. G. Skinner, and W. Shive, J. Biol. Chem., 232, 159 (1958).
- (3) C. G. Skinner, G. F. McKenna, T. J. McCord, and W. Shive, *Tex. Rep. Biol. Med.*, **16**, 493 (1958).
- (4) K. Hayashi, C. G. Skinner, and W. Shive, ibid., 19, 277 (1961).
- (5) B. A. Ivin and V. G. Nemets, Zh. Obshch. Khim., 35, 1294 (1965); Chem. Abstr., 63, 11557e (1965).
- (6) E. M. Lansford, W. M. Harding, and W. Shive, Arch. Biochem. Biophys., 73, 180 (1958).

Potential Anticancer Agents. 4. Schiff Bases from Benzaldehyde Nitrogen Mustards

D. R. Shekawat, S. S. Sabnis, and C. V. Deliwala*

Department of Chemotherapy, Haffkine Institute, Bombay-12, India. Received April 28, 1972

We have reported in an earlier communication the synthesis and study of Schiff bases from substituted benzaldehyde N mustards and various arylamines.¹ A number of compounds from this series displayed significant activity against Dunning leukemia (solid), lymphoid leukemia (L 1210), and Walker carcinosarcoma 256 (intramuscular). Compounds derived from 4-[N,N-bis(2-chloroethyl)amino]*m*-anisaldehyde were in general more active against L 1210 lymphoid leukemia. A significant observation in our earlier work was that the presence of a halogen in the meta position of the arylamines induced activity of a high order. Further, the introduction of an additional halogen group in another available meta position of the aniline moiety considerably enhances the antileukemic activity with reduction in toxicity. The work has now been extended and Schiff bases of structure I from various 3,5-dihalo-substituted anilines have been prepared and studied for biological activity.



Chemistry. The Schiff bases (Table I) were obtained as monohydrochlorides by heating the requisite pure amine hydrochlorides with mustard aldehydes in $EtOH^1$ and were found to be of analytical purity with yields varying between 60 and 75%.

Biological Results. Fourteen representative compounds were screened for antitumor activity by C.C.N.S.C. The re-

$X \xrightarrow{R_2 R_1} N = CH - O \xrightarrow{K_2 R_1} N(CH_2CH_2CI)_2$									
x/									
No.	х	Y	R ₁	R ₂	Mp, °C	Formula ^a			
1	Cl	Cl	Н	CH3	218-220	$C_{18}H_{17}Cl_{5}N_{2}\cdot HCl$			
2	Cl	Cl	OCH3	Н	203-205	C ₁₈ H ₁₇ Cl ₅ N ₂ O ·HCl			
3	Cl	Cl	OC ₂ H ₅	Н	195-197	C ₁₉ H ₁₉ Cl ₅ N ₂ O·HCl			
4	Cl	COOH	Н	CH3	247	C ₁₉ H ₁₈ Cl ₄ N ₂ O ₂ ·HCl			
5	C1	COOH	OCH3	Н	140-141	C ₁₉ H ₁₈ Cl ₄ N ₂ O ₃ ·HCl			
6	Cl	COOH	OC₂H₅	Н	167-169	C ₂₀ H ₂₀ Cl ₄ N ₂ O ₃ ·HCl			
7	C1	ОН	Н	Н	150-152	C ₁₇ H ₁₆ Cl ₄ N ₂ O·HCl			
8	Cl	ОН	Н	CH3	240-242	C ₁₈ H ₁₈ Cl ₄ N ₂ O·HCl			
9	C1	OH	OCH3	Н	255-256	$C_{18}H_{18}Cl_4N_2O_2 \cdot HCl$			
10	Cl	OH	OC ₂ H ₅	Н	235-238	$C_{19}H_{20}Cl_4N_2O_2$			
11	C1	OCH3	Н	CH ₂	221-222	C ₁₉ H ₂₀ Cl ₄ N ₂ O·HCl			
12	Cl	OCH,	OCH3	Н	168-170	$C_{19}H_{20}Cl_4N_2O_2 \cdot HCl$			
13	Cl	OCH ₃	OC ₂ H ₅	H	135-138	$C_{20}H_{22}Cl_4N_2O_2 \cdot HCl$			
14	C1	OC ₂ H ₅	H	Н	232-235	C ₁₉ H ₂₀ Cl ₄ N ₂ O·HCl			
15	C1	OC_2H_s	Н	CH3	227-229	C ₂₀ H ₂₂ Cl ₄ N ₂ O · HCl			
16	C1	OC ₂ H ₅	OCH3	Н	145-148	$C_{20}H_{22}Cl_4N_2O_2 \cdot HCl$			
17	Br	Н	H	CH3	230-232	$C_{18}H_{18}Br_2Cl_2N_2 \cdot HCl$			
18	Br	Н	OCH ₃	Н	152-154	C ₁₈ H ₁₈ Br ₂ Cl ₂ N ₂ O ·HCl			
19	Br	H	OC ₂ H ₅	Н	187-190	C ₁₉ H ₂₀ Br ₂ Cl ₂ N ₂ O·HCl			
20	Br	COOH	H	CH ₃	170-172	$C_{19}H_{18}Br_2Cl_2N_2O_2 \cdot HCl$			
21	Br	COOH	OC_2H_5	H	180-182	$C_{20}H_{20}Br_2Cl_2N_2O_3 \cdot HCl$			
22	Br	ОН	Н	Н	215-218	C ₁₇ H ₁₆ Br ₂ Cl ₂ N ₂ O·HCl			
23	Br	OH	Н	CH3	235-236	C ₁₈ H ₁₈ Br ₂ Cl ₂ N ₂ O·HCl			
24	Br	ОН	OCH ₃	Н	230	$C_{18}H_{18}Br_2Cl_2N_2O_2 \cdot HCl$			
25	Br	OH	OC ₂ H ₅	Н	230-232	$C_{19}H_{20}Br_2Cl_2N_2O_2 \cdot HCl$			
26	Br	OCH3	Н	CH3	222-224	C ₁₉ H ₂₀ Br ₂ Cl ₂ N ₂ O · HCl			
27	Br	OCH3	OCH ₃	Н	175-177	$C_{19}H_{20}Br_2Cl_2N_2O_2 \cdot HCl$			
28	Br	OCH₃	OC ₂ H ₅	Н	142-144	$C_{20}H_{22}Br_2Cl_2N_2O_2 \cdot HCl$			
29	Br	OC ₂ H ₅	Н	CH3	230-233	$C_{20}H_{22}Br_2Cl_2N_2O \cdot HCl$			
30	Br	OC ₂ H ₅	OCH ₃	H	170-172	$C_{20}H_{22}Br_2Cl_2N_2O_2 \cdot HCl$			

^aAnalyzed correctly for C, H, and N.

sults of 11 active compounds are presented in Table II.[†] Compounds 8, 17, and 23 were inactive.

Present data also confirm the earlier observation that Schiff bases from 4-[N,N-bis(2-chloroethyl)amino]-m-anisaldehyde are in general significantly more active against L 1210 lymphoid leukemia. Compounds 24 and 27 have also shown good activity against Walker carcinosarcoma 256 (intramuscular). The introduction of an OH group between the two halogens has improved the activity of Schiff bases (9, 10, 24) but the etherification of OH resulted in the decrease of activity (12, 27, 30). The replacement of OMe by OEt in 9 increased activity and reduced the toxicity (10). Against 3PS lympocytic leukemia, 9, 18, 24, and 26 showed good activity.

Experimental Section^{‡,§}

Intermediates. Amines needed were prepared by reduction of the corresponding nitro compounds with Sn and HCl. 3,4,5-Trichloronitrobenzene² and 3,5-dibromonitrobenzene² were prepared by the hydrolysis of corresponding benzamides.³ 2,6-Dihalo-4nitroanisoles or phenetoles were prepared by heating potassium salt of appropriate phenols with alkyl sulfate.4

2,6-Dichloro-p-phenetidine. To a mixture of 2.3 g (0.01 mole) of 2,6-dichloro-4-nitrophenetole and concd HCl (20 ml) was added gradually tin metal (4 g). EtOH (2 ml) was then added, the mixt was warmed on steam bath for a few min and left overnight at room temp. The next day it was basified (10% aqueous NaOH) and extd (Et₂O). Removal of solvent and crystn gave 1.62 g (80%) of the amine, mp 105-107°. Anal. (C8H9Cl2NO) C, H, N.

4-({4-[N,N-Bis(2-chloroethyl)amino]-3-ethoxybenzylidene}amino)-2,6-dibromophenol·HCl. To a solution of 2,6-dibromo-4aminophenol · HCl (3.0 g, 0.01 mole) in dry warm EtOH was added a concd EtOH soln of 4-[N,N-bis(2-chloroethyl)amino]-3-ethoxybenzaldehyde (2.9 g, 0.01 mole). The resulting dark red soln on standing and cooling in ice deposited a crystn solid which was filtd and washed (abs EtOH, Et_2O) to give the pure hydrochloride (3.4 g, 70%) of the Schiff base. All the other Schiff bases were similarly prepared and are recorded in Table I.

Acknowledgments. We are greatly indebted to Dr. H. B. Wood, Chief, Drug Development Branch, Cancer Chemotherapy National Service Center, for his cooperation and for making the screening data available and to Mr. M. T. Jaokar for microanalyses. Thanks are due to Dr. N. K. Dutta, Director, Haffkine Institute, Bombay, for providing facilities to carry out the present work.

References

- (1) M. G. Dhapalapur, S. S. Sabnis, and C. V. Deliwala, J. Med. Chem., 11, 1014 (1968).
- (2) R. G. Shepherd, J. Org. Chem., 12, 275 (1947).
- (3) Merck and Co. Inc., Netherlands Application 6,412,382 (May 3, 1965); Chem. Abstr., 63, 9881 (1965).
- (4) C. de. Traz, Helv. Chim. Acta, 30, 232 (1947).

⁺Antitumor screening data represented by this table will appear following these pages in the microfilm edition of this volume of the journal. Single copies may be obtained from the Business Operations Office, Books and Journals Division, American Chemical Society, 1155 Sixteenth St., N.W., Washington, D. C. 20036. Remit check or money order for \$3.00 for photocopy or \$2.00 for microfiche, referring to code number JMED-72-1196.

[‡]Analytical results obtained were within ±0.4% of theor values. § Melting points are capillary melting points and are uncor.